The Fox Chase Chemical Diversity Center, Inc. (FCCDC)

 

The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase II STTR Entitled “Optimizing a Stapled-Peptide that Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis” (R42AI170552)

 

Doylestown, PA. June 21, 2022 - FCCDC is pleased to announce that it has been award a Phase II STTR entitled “Optimizing a Stapled-Peptide that Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis” (R42AI170552) working with Prof. Robert Ricciardi of the University of Pennsylvania.